ArticleAmerican journal of translational research2024
Comprehensive analysis of the pituitary tumor-transforming gene (PTTG) family in lung adenocarcinoma: diagnostic, prognostic, and therapeutic implications.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLung adenocarcinoma (LUAD) is a prevalent form of non-small cell lung cancer with high morbidity and mortality rates. Identifying molecular markers and therapeutic targets is crucial for improving LUAD diagnosis and treatment. Pituitary tumor-transforming gene (PTTG) family members, PTTG1, PTTG2, and PTTG3P, have been linked to several malignancies; however, it is unclear how these genes relate to LUAD. The current retrospective study investigates the diagnostic, prognostic, and therapeutic importance of PTTG genes in LUAD.
methodsWe used detailed in silico and in vitro experiments involving cell lines for experimental design.
resultsUsing RT-qPCR, we documented that PTTG1, PTTG2, and PTTG3P are significantly up-regulated in LUAD cell lines compared to controls, with PTTG2 showing the highest diagnostic potential (AUC = 1.0). Promoter methylation analysis revealed hypomethylation in LUAD samples, particularly for PTTG3P, further supporting its diagnostic relevance. Immunohistochemical staining confirmed overexpression of PTTG1 and PTTG2 proteins in LUAD tissue samples. The mutational analysis highlighted PTTG2 as the most frequently mutated gene within the PTTG family in LUAD samples, with mutations primarily being missense types. Survival analysis demonstrated that high expression of PTTG genes is associated with poorer overall survival, indicating their prognostic value. Gene enrichment analysis suggested that PTTG genes are involved in critical cancer-related pathways and cellular processes. Functional assays following siRNA-mediated knockdown of PTTG genes in A549 cells showed a significant reduction in cell proliferation. Lastly, drug sensitivity analysis revealed strong correlations between PTTG1/PTTG3P expression and resistance to various anticancer drugs.
conclusionThe findings of the current study highlight the potential of PTTG genes as diagnostic biomarkers, prognostic indicators, and therapeutic targets in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.